Apsr Respiratory Updates

Idiopathic Pulmonary Fibrosis: Clinically Meaningful Primary Endpoints in Phase 3 Clinical Trials 3 Hot on the breath: Mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good 4 Idiopathic Pulmonary Fibrosis: Lung Function is a Clinically Meaningful Endpoint for Phase 3 Trials 4 III. About Sarcoidosis 5 A Novel Sarcoidosis Risk Locus for Europeans on Chromosome 11q13.1 5 Sarcoidosis-related Mortality in the United States from 1988 to 2007 5 Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis 6 Development of a sarcoidosis murine lung granuloma model using Mycobacterium superoxide dismutase A peptide. 6